The development of biomarkers based on quantitative imaging provides powerful non-invasive and cost-effective diagnostic tools for stratified medicine. Brainomix Limited, a start-up company from the University of Oxford, aims to become leaders in imaging biomarkers for neurological and cerebrovascular disorders.
Having the right people in place is essential to our success. Find out more about the people behind Brainomix.
We aim to become leaders in imaging biomarkers for neurological disorders.
The clinical need
e-ASPECTS software automatically assesses and quantifies early ischaemic brain damage on CT scans....
- Speed up the decision making process improving patient outcomes
- Reduce hospitalisation costs by limiting length of stay
- Increase the uptake of stroke treatments.
Try e-ASPECTS instant online demo system
International Journal of Stroke Publication
Dec. 14, 2016
Oxford – A new clinical study was conducted by Anglia Ruskin Clinical Trials Unit reporting the performance of e-ASPECTS. In this multi-centre study, non-contrast enhanced computed tomography (NCCT) images from...
Brainomix Completes a £1,5 Million Investment Round
Oct. 17, 2016
Oxford – Brainomix Ltd, a company developing imaging biomarkers for neurological and cerebrovascular disorders, announced today that it has completed a £1.5 million investment round. This will enable Brainomix...
Brainomix at neuroRAD 2016 Conference
Oct. 4, 2016
Oxford – Brainomix is attending the 2016 neuroRAD conference (5-8 Oct, Cologne, Germany) The conference hosts the annual meetings of the German and Austrian neuroradiology societies. This year’s event focuses,...
Discover press releases, news articles and social media updates from Brainomix.
@OxfordAHSN June 30, 2015
@Brainomix benefits for patients, for clinicians and hospital spend! #OxTechShowcase - must be a winner for us all
Delivering efficient and effective healthcare has never been more important, and innovation is central to making that happen.